Insulin Glargine
Approved · EMAAlso known as Basaglar, Lantus, Rezvoglar, Semglee+6 more
Basaglar, Lantus, Rezvoglar, Semglee, Soliqua, Toujeo, Insulina glargina, INSULIN,GLARGINE,HUMAN/rDNA, Insulin glargine recombinant, insulin glargine, human recombin. analog.
Recent clinical, regulatory, research and industry developments relating to this drug.
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR): A Randomized Noninferiority Trial
Drug Safety Update: Insulin glargine: studies of possible cancer link
Approval: Abasaglar (previously Abasria) (EMA)
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
— 70 supporting evidence families · 25 well-powered no-effect results
Confidence is moderated by well-powered no-effect evidence and limited publication incorporation, despite broad trial support.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Evidence ↗Indication: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Evidence ↗Indication: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Diabetes care2
- Diabetes, obesity & metabolism2
- Academic emergency medicine : official journal of the Society for Academic Emergency Medicine1
- Annals of internal medicine1
- Diabetic medicine : a journal of the British Diabetic Association1
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1
- Diamant M2
- Endahl L2
- Onishi Y2
- An Z1
- Aroda VR1
- Banuelos R1
- Bode B1
- Brandt S1
- VU University Medical Center2
- Autonomous University of Barcelona1
- Baskent University Hospital1
- Clinical Development & Research-Diabetes & Obesity1
- Dallas Diabetes and Endocrine Center at Medical City1
- Diabetes Care & Research Centre1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Insulin Glargine in the shared literature.
Studied across 2 of the same disease areas as Insulin Glargine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.